Details

Autor(en) / Beteiligte

• Hamadeh, Issam S.
• Shekarkhand, Tala
• Rueda, Colin
• Firestone, Ross S.
• Wang, Alice X.
• Korde, Neha
• Hultcrantz, Malin L.
• Lesokhin, Alexander M.
• Mailankody, Sham
• Hassoun, Hani
• Shah, Urvi A.
• Maclachlan, Kylee
• Rajeeve, Sridevi
• Patel, Dhwani
• Shah, Gunjan L.
• Scordo, Michael
• Lahoud, Oscar B.
• Chung, David J.
• Landau, Heather J.
• Giralt, Sergio
• Usmani, Saad Z.
• Tan, Carlyn R.

Titel

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Ist Teil von

• Blood advances, 2024-06, Vol.8 (12), p.3038-3044

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• •Patients with multiple myeloma previously treated with T-cell redirection therapy have a significantly lower risk of developing CRS with Tec.•Patients with high-risk cytogenetic features were at a low risk of developing CRS with Tec. [Display omitted] Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure to other T-cell redirection therapies. A retrospective chart review was performed to identify patients who completed the Tec step-up dosing phase between November 2022 and November 2023. Patients were divided into 2 cohorts based on prior exposure to T-cell redirection therapy (cohort 1: T-cell redirection therapy experienced; cohort 2: T-cell redirection therapy naïve). The primary objective was to compare the differences in the rates of CRS between the 2 cohorts. Univariate and multivariate logistic regression analyses were performed to assess the association between CRS rates with Tec and prior treatment with T-cell redirection therapy. A total of 72 patients were included in the analysis (27 in cohort 1 and 45 in cohort 2). The CRS rates were significantly lower in cohort 1 (37%, n = 10) compared with cohort 2 (80%, n = 36; P = .0004). Based on multivariate logistic regression analysis, patients without prior exposure to T-cell redirection therapy (cohort 2) had about a fourfold increase in the incidence of CRS (95% confidence interval, 1.40-14.90; P = .0002) with Tec. In our study, prior exposure to T-cell redirection therapy reduced the risk of CRS with Tec during the step-up dosing phase. This observation will allow for the optimization of CRS prophylactic strategies for Tec.